4.1 Article

Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection

期刊

JOURNAL OF BIOPHARMACEUTICAL STATISTICS
卷 24, 期 3, 页码 685-705

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/10543406.2014.888569

关键词

Sample size; Predictive probabilities; Sequential design; Bayesian adaptive trial design

向作者/读者索取更多资源

We present a Bayesian adaptive design for a confirmatory trial to select a trial's sample size based on accumulating data. During accrual, frequent sample size selection analyses are made and predictive probabilities are used to determine whether the current sample size is sufficient or whether continuing accrual would be futile. The algorithm explicitly accounts for complete follow-up of all patients before the primary analysis is conducted. We refer to this as a Goldilocks trial design, as it is constantly asking the question, Is the sample size too big, too small, or just right? We describe the adaptive sample size algorithm, describe how the design parameters should be chosen, and show examples for dichotomous and time-to-event endpoints.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Pharmacology & Pharmacy

Potential Statistical Issues Between Designers and Regulators in Confirmatory Basket, Umbrella, and Platform Trials

Scott M. Berry

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

Article Multidisciplinary Sciences

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study

Andrew Ip, Donald A. Berry, Eric Hansen, Andre H. Goy, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M. Berry, Nicholas S. Berry, Shivam Mathura, Ihor S. Sawczuk, Noa Biran, Ronaldo C. Go, Steven Sperber, Julia A. Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M. Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L. Timmapuri, Joseph P. Underwood, Gregory Sugalski, Carol Barsky, Daniel W. Varga, Arif Asif, Joseph C. Landolfi, Stuart L. Goldberg

PLOS ONE (2020)

Article Medicine, Research & Experimental

Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial

Brett L. Houston, Patrick R. Lawler, Ewan C. Goligher, Michael E. Farkouh, Charlotte Bradbury, Marc Carrier, Vlad Dzavik, Dean A. Fergusson, Robert A. Fowler, Jean-Phillippe Galanaud, Peter L. Gross, Emily G. McDonald, Mansoor Husain, Susan R. Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S. Slutsky, Alexis F. Turgeon, Scott M. Berry, Robert S. Rosenson, Jorge Escobedo, Jose C. Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski

CLINICAL TRIALS (2020)

Article Medicine, General & Internal

Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients

Katherine Moll Reitz, Christopher W. Seymour, Jennifer Vates, Melanie Quintana, Kert Viele, Michelle Detry, Michael Morowitz, Alison Morris, Barbara Methe, Jason Kennedy, Brian Zuckerbraun, Timothy D. Girard, Oscar C. Marroquin, Stephen Esper, Jennifer Holder-Murray, Anne B. Newman, Scott Berry, Derek C. Angus, Matthew Neal

BMJ OPEN (2020)

Article Mathematical & Computational Biology

Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy

Stephen L. Lake, Melanie A. Quintana, Kristine Broglio, Jennifer Panagoulias, Scott M. Berry, Michael A. Panzara

Summary: A Bayesian adaptive design was proposed for a clinical trial in Duchenne muscular dystrophy, aiming to demonstrate treatment efficacy and identify early success on a biomarker. The trial incorporated placebo augmentation using data from past clinical trials and was selected for the US FDA Complex Innovative Trial Design Pilot Meeting Program, with the experience summarized.

STATISTICS IN MEDICINE (2021)

Article Genetics & Heredity

Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study

Nuria Carrillo, May C. Malicdan, Petcharat Leoyklang, Joseph A. Shrader, Galen Joe, Christina Slota, John Perreault, John D. Heiss, Bradley Class, Chia-Ying Liu, Kennan Bradley, Colleen Jodarski, Carla Ciccone, Claire Driscoll, Rebecca Parks, Scott Van Wart, Levent Bayman, Christopher S. Coffey, Melanie Quintana, Scott M. Berry, Marjan Huizing, William A. Gahl

Summary: This study evaluated the safety and efficacy of ManNAc in patients with GNE myopathy and found long-term safety, biochemical efficacy consistent with the intended mechanism of action, and preliminary evidence of clinical efficacy in patients.

GENETICS IN MEDICINE (2021)

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher, Charlotte A. Bradbury, Bryan J. McVerry, Patrick R. Lawler, Jeffrey S. Berger, Michelle N. Gong, Marc Carrier, Harmony R. Reynolds, Anand Kumar, Alexis F. Turgeon, Lucy Z. Kornblith, Susan R. Kahn, John C. Marshall, Keri S. Kim, Brett L. Houston, Lennie P. G. Derde, Mary Cushman, Tobias Tritschler, Derek C. Angus, Lucas C. Godoy, Zoe McQuilten, Bridget-Anne Kirwan, Michael E. Farkouh, Maria M. Brooks, Roger J. Lewis, Lindsay R. Berry, Elizabeth Lorenzi, Anthony C. Gordon, Scott M. Berry, Colin J. McArthur, Matthew D. Neal, Judith S. Hochman, Steven A. Webb, Ryan Zarychanski, Tania Ahuja, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Lisa Baumann Kreuziger, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen-Ting Chen, Allen C. Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Aira Contreras, Todd W. Costantini, Sophie de Brouwer, Michelle A. Detry, Abhijit Duggal, Vladimir Dzavik, Mark B. Effron, Heather F. Eng, Jorge Escobedo, Lise J. Estcourt, Brendan M. Everett, Dean A. Fergusson, Mark Fitzgerald, Robert A. Fowler, Joshua D. Froess, Zhuxuan Fu, Jean P. Galanaud, Benjamin T. Galen, Sheetal Gandotra, Timothy D. Girard, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Y. Greenstein, Peter L. Gross, Rashan Haniffa, Sheila M. Hegde, Carolyn M. Hendrickson, Alisa M. Higgins, Alexander A. Hindenburg, Aluko A. Hope, James M. Horowitz, Christopher M. Horvat, David T. Huang, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma M. Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J. King, Aaron E. Kornblith, Matthew E. Kutcher, Michael A. Laffan, Francois Lamontagne, Gregoire Le Gal, Christine M. Leeper, Eric S. Leifer, George Lim, Felipe Gallego Lima, Kelsey Linstrum, Edward Litton, Jose Lopez-Sendon, Sylvain A. Lother, Nicole Marten, Andrea Saud Marinez, Mary Martinez, Eduardo Mateos Garcia, Stavroula Mavromichalis, Daniel F. McAuley, Emily G. McDonald, Anna McGlothlin, Shay P. McGuinness, Saskia Middeldorp, Stephanie K. Montgomery, Paul R. Mouncey, Srinivas Murthy, Girish B. Nair, Rahul Nair, Alistair D. Nichol, Jose C. Nicolau, Brenda Nunez-Garcia, John J. Park, Pauline K. Park, Rachael L. Parke, Jane C. Parker, Sam Parnia, Jonathan D. Paul, Mauricio Pompilio, John G. Quigley, Robert S. Rosenson, Natalia S. Rost, Kathryn Rowan, Fernanda O. Santos, Marlene Santos, Mayler O. Santos, Lewis Satterwhite, Christina T. Saunders, Jake Schreiber, Roger E. G. Schutgens, Christopher W. Seymour, Deborah M. Siegal, Delcio G. Silva, Aneesh B. Singhal, Arthur S. Slutsky, Dayna Solvason, Anne M. Turner, Wilma Van Bentum-Puijk, Frank L. van de Veerdonk, Sean van Diepen, Gloria Vazquez-Grande, Lana Wahid, Vanessa Wareham, R. Jay Widmer, Jennifer G. Wilson, Eugene Yuriditsky, Yongqi Zhong

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Multidisciplinary Sciences

Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19

Donald A. Berry, Andrew Ip, Brett E. Lewis, Scott M. Berry, Nicholas S. Berry, Mary MrKulic, Virginia Gadalla, Burcu Sat, Kristen Wright, Michelle Serna, Rashmi Unawane, Katerina Trpeski, Michael Koropsak, Puneet Kaur, Zachary Sica, Andrew McConnell, Urszula Bednarz, Michael Marafelias, Andre H. Goy, Andrew L. Pecora, Ihor S. Sawczuk, Stuart L. Goldberg

Summary: A risk score utilizing six variables can predict mortality within 40 days of hospitalization for COVID-19 in patients within a hospital network in New Jersey, USA.

PLOS ONE (2021)

Review Infectious Diseases

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Cathrine Axfors, Perrine Janiaud, Andreas M. Schmitt, Janneke Van't Hooft, Emily R. Smith, Noah A. Haber, Akin Abayomi, Manal Abduljalil, Abdulkarim Abdulrahman, Yeny Acosta-Ampudia, Manuela Aguilar-Guisado, Farah Al-Beidh, Marissa M. Alejandria, Rachelle N. Alfonso, Mohammad Ali, Manaf AlQahtani, Alaa AlZamrooni, Juan-Manuel Anaya, Mark Angelo C. Ang, Ismael F. Aomar, Luis E. Argumanis, Alexander Averyanov, Vladimir P. Baklaushev, Olga Balionis, Thomas Benfield, Scott Berry, Nadia Birocco, Lynn B. Bonifacio, Asha C. Bowen, Abbie Bown, Carlos Cabello-Gutierrez, Bernardo Camacho, Adrian Camacho-Ortiz, Sally Campbell-Lee, Damon H. Cao, Ana Cardesa, Jose M. Carnate, German Jr J. Castillo, Rossana Cavallo, Fazle R. Chowdhury, Forhad U. H. Chowdhury, Giovannino Ciccone, Antonella Cingolani, Fresthel Monica M. Climacosa, Veerle Compernolle, Carlo Francisco N. Cortez, Abel Costa Neto, Sergio D'Antico, James Daly, Franca Danielle, Joshua S. Davis, Francesco Giuseppe De Rosa, Justin T. Denholm, Claudia M. Denkinger, Daniel Desmecht, Juan C. Diaz-Coronado, Juan A. Diaz Ponce-Medrano, Anne-Francoise Donneau, Teresita E. Dumagay, Susanna Dunachie, Cecile C. Dungog, Olufemi Erinoso, Ivy Mae S. Escasa, Lise J. Estcourt, Amy Evans, Agnes L. M. Evasan, Christian J. Fareli, Veronica Fernandez-Sanchez, Claudia Galassi, Juan E. Gallo, Patricia J. Garcia, Patricia L. Garcia, Jesus A. Garcia, Mutien Garigliany, Elvira Garza-Gonzalez, Deonne Thaddeus Gauiran, Paula A. Gaviria Garcia, Jose-Antonio Giron-Gonzalez, David Gomez-Almaguer, Anthony C. Gordon, Andre Gothot, Jeser Santiago Grass Guaqueta, Cameron Green, David Grimaldi, Naomi E. Hammond, Heli Harvala, Francisco M. Heralde, Jesica Herrick, Alisa M. Higgins, Thomas E. Hills, Jennifer Hines, Karin Holm, Ashraful Hoque, Eric Hoste, Jose M. Ignacio, Alexander Ivanov, Maike Janssen, Jeffrey H. Jennings, Vivekanand Jha, Ruby Anne N. King, Jens Kjeldsen-Kragh, Paul Klenerman, Aditya Kotecha, Fiorella Krapp, Luciana Labanca, Emma Laing, Mona Landin-Olsson, Pierre-Francois Laterre, Lyn-Li Lim, Jodor Lim, Oskar Ljungquist, Jorge M. Llaca-Diaz, Concepcion Lopez-Robles, Salvador Lopez-Cardenas, Ileana Lopez-Plaza, Josephine Anne C. Lucero, Maria Lundgren, Juan Macias, Sandy C. Maganito, Anna Flor G. Malundo, Ruben D. Manrique, Paola M. Manzini, Miguel Marcos, Ignacio Marquez, Francisco Javier Martinez-Marcos, Ana M. Mata, Colin J. McArthur, Zoe K. McQuilten, Bryan J. McVerry, David K. Menon, Geert Meyfroidt, Ma Angelina L. Mirasol, Benoit Misset, James S. Molton, Alric Mondragon, Diana M. Monsalve, Parastoo Moradi Choghakabodi, Susan C. Morpeth, Paul R. Mouncey, Michel Moutschen, Carsten Muller-Tidow, Erin Murphy, Tome Najdovski, Alistair D. Nichol, Henrik Nielsen, Richard M. Novak, Matthew V. N. O'Sullivan, Julian Olalla, Akin Osibogun, Bodunrin Osikomaiya, Salvador Oyonarte, Juan M. Pardo-Oviedo, Mahesh C. Patel, David L. Paterson, Carlos A. Pena-Perez, Angel A. Perez-Calatayud, Eduardo Perez-Alba, Anastasia Perkina, Naomi Perry, Mandana Pouladzadeh, Inmaculada Poyato, David J. Price, Anne Kristine H. Quero, Md M. Rahman, Md S. Rahman, Mayur Ramesh, Carolina Ramirez-Santana, Magnus Rasmussen, Megan A. Rees, Eduardo Rego, Jason A. Roberts, David J. Roberts, Yhojan Rodriguez, Jesus Rodriguez-Bano, Benjamin A. Rogers, Manuel Rojas, Alberto Romero, Kathryn M. Rowan, Fabio Saccona, Mehdi Safdarian, Maria Clariza M. Santos, Joe Sasadeusz, Gitana Scozzari, Manu Shankar-Hari, Gorav Sharma, Thomas Snelling, Alonso Soto, Pedrito Y. Tagayuna, Amy Tang, Geneva Tatem, Luciana Teofili, Steven Y. C. Tong, Alexis F. Turgeon, Januario D. Veloso, Balasubramanian Venkatesh, Yanet Ventura-Enriquez, Steve A. Webb, Lothar Wiese, Christian Wiken, Erica M. Wood, Gaukhar M. Yusubalieva, Kai Zacharowski, Ryan Zarychanski, Nina Khanna, David Moher, Steven N. Goodman, John P. A. Ioannidis, Lars G. Hemkens

Summary: This study assessed the benefits of convalescent plasma treatment compared to placebo or no treatment in COVID-19 patients and found that convalescent plasma treatment did not reduce all-cause mortality. The researchers recommend that convalescent plasma treatment for COVID-19 patients should not be used outside of randomized trials. Collaboration among trial investigators can inform both evidence generation and evidence application in patient care.

BMC INFECTIOUS DISEASES (2021)

Article Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Harny, Marick Lae, Fabien Reyal, Gabes S. Sonke, Tessa G. Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martin, Maria del Monte-Millan, Sara Lopez-Tarruella, Judy C. Boughey, Matthew P. Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B. Edge, Jean E. Abraham, John M. S. Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S. Thomas, David Cameron, Ashley Graham, Peter Hail, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanko Sharma, Angela M. DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J. van't Veer, Laura J. Esserman, W. Fraser Symmans

Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.

LANCET ONCOLOGY (2022)

Article Multidisciplinary Sciences

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele

Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.

NATURE COMMUNICATIONS (2021)

Article Oncology

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. Van't Veer, Donald A. Berry, Laura J. Esserman

Summary: The study found that further development of anti-IGF-1R therapy will require better control of drug-induced hyperglycemia and the development of more predictive biomarkers.

NPJ BREAST CANCER (2021)

Correction Medicine, Research & Experimental

Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses (vol 23, 534, 2022)

Pepa Bruce, Kate Ainscough, Lee Hatter, Irene Braithwaite, Lindsay R. Berry, Mark Fitzgerald, Thomas Hills, Kathy Brickell, David Cosgrave, Alex Semprini, Susan Morpeth, Scott Berry, Peter Doran, Paul Young, Richard Beasley, Alistair Nichol

TRIALS (2022)

Article Medicine, Research & Experimental

Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses

Pepa Bruce Metadata, Kate Ainscough, Lee Hatter, Irene Braithwaite, Lindsay R. Berry, Mark Fitzgerald, Thomas Hills, Kathy Brickell, David Cosgrave, Alex Semprini, Susan Morpeth, Scott Berry, Peter Doran, Paul Young, Richard Beasley, Alistair Nichol

Summary: This article presents a practical model using Bayesian methods for rapid determination of the effectiveness of prophylactic agents in preventing COVID-19, but recruitment for the actual study did not start due to reduced COVID-19 cases in New Zealand and concerns about the efficacy and risks of HCQ treatment. The model can be easily adapted for other potential prophylactic agents and pathogens, and should be shared and incorporated into future pandemic preparedness planning.

TRIALS (2022)

Article Medicine, Research & Experimental

The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials

Benjamin R. Saville, Donald A. Berry, Nicholas S. Berry, Kert Viele, Scott M. Berry

Summary: This study proposes a new analysis method, the Bayesian Time Machine, to address the issue of temporal drift in multi-arm platform trials. The results show that the Bayesian Time Machine provides better estimation of treatment effects and favorable testing properties compared to analyses using either concurrent or pooled controls.

CLINICAL TRIALS (2022)

暂无数据